¹**Free fatty acids accelerate** β**-cell death in type 1 diabetes**

2

3 Emily C. Elliott^{1#}, Soumyadeep Sakar^{1#}, Lisa Bramer¹, Meagan Burnet¹, Young-Mo 4 Kim¹, Xiaoyan Yi², Igor L. Estevao¹, Marian Rewers³, Xiaolu A. Cambronne⁴, Kendra 5 Vehik⁵, Rafael Arrojo e Drigo⁶, Thomas O. Metz¹, Decio L. Eizirik², Bobbie-Jo M. Webb-

- 6 Robertson¹, Raghavendra G. Mirmira⁷, Ernesto S. Nakayasu^{1,*}
- 7
- 8 ¹ Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, 9 USA.
- 10 ²ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles 11 (ULB), Brussels, Belgium.
- ³ Barbara Davis Center for Diabetes, School of Medicine, University of Colorado 13 Anschutz Medical Campus, Aurora, CO, USA.
- ⁴ Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
- ⁵ Health Informatics Institute, Morsani College of Medicine, University of South Florida, 16 Tampa, Florida, USA.
- ⁶ Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, 18 TN, USA.
- ⁷ Kovler Diabetes Center and Department of Medicine, The University of Chicago, 20 Chicago, IL, USA.
- 21
- 22 #Equally contributing authors.
- 23 *Correspondence: ernesto.nakayasu@pnnl.gov (to E.S.N.)
- 24
- 25

26 **Abstract**

27 Type 1 diabetes (T1D) results from autoimmune destruction of the insulin producing 28 pancreatic β cells. The body's lipid metabolism is strongly regulated during this process 29 but there is a need to understand how this regulation contributes to the β-cell death. 29 but there is a need to understand how this regulation contributes to the β-cell death.
30 Here, we show that fatty acids are released from plasma lipoproteins in children during Here, we show that fatty acids are released from plasma lipoproteins in children during 31 islet autoimmunity, prior to T1D onset. These fatty acids (FFAs) enhanced cytokine-32 mediated apoptosis in cultured insulin-producing cells by downregulating the production 33 of nicotinamide adenosine dinucleotide (NAD) via its salvage pathway, as well as 34 deregulated central carbon metabolism and impaired levels of ATP. Downregulation of 35 the NAD salvage pathway and central carbon metabolism enzymes were further 36 observed during T1D development, supporting that the pathways for NAD and energy 37 production are compromised *in vivo*. Our findings show that fatty acids are released 38 during islet autoimmunity, accelerating disease development through impaired NAD 39 metabolism.

41 **Introduction**

42 Type 1 diabetes (T1D) affects an estimated 8.4 million people worldwide and reduces 43 the life expectancy of those affected by over a decade¹⁻³. The disease results from the 44 progressive loss of insulin-producing β cells of the pancreas via an autoimmune
45 response, leading to the inability to control blood glucose levels^{4,5}. Selected human response, leading to the inability to control blood glucose levels^{4,5}. Selected human 46 leukocyte antigen (*HLA*) genotypes are risk factors, but only 5% of individuals carrying 47 those genotypes eventually develop $T1D^{6-8}$, suggesting the contribution of additional 48 biotic and environmental factors⁹. The body metabolism may be one of these factors as 49 many of its aspects have been associated with T1D development⁹⁻¹². However, little is 50 known about how specific metabolic pathways mechanistically contribute to disease 51 development.

52 Among the metabolic processes, the body lipid metabolism is one of the most regulated 53 during T1D development^{10,12-14}. Plasma lipoproteins are regulated in children even prior 54 to the onset of islet autoimmunity (herein referred to as seroconversion and clinically 55 diagnosed by the appearance of circulating islet autoantibodies)¹⁵. There is also a 56 decrease in the levels of plasma phosphatidylcholine and triacylglycerols during T1D 57 development¹⁰. Similarly, in human islets treated with the pro-inflammatory cytokines IL-58 1β and IFN-γ that mimic the insulitis environment, there is a decrease in triacylglycerol
59 levels¹⁶. Other lipids, such as short-chain fatty acids, drive inflammation of the intestine. levels¹⁶. Other lipids, such as short-chain fatty acids, drive inflammation of the intestine, 60 increases intestinal permeability, and augments the exposure to putative dietary 61 antigens¹⁷. Conversely, diets enriched in omega-3 fatty acids improve intestinal integrity 62 and reduce the onset of T1D in mice^{18,19}. Omega-3-rich diet can also diminish the risk of 63 children to develop islet autoimmunity²⁰. Mechanistically, omega-3 fatty acids reduce 64 apoptosis of insulin-producing cells by downregulating the methylation of the *ADPRHL2* 65 gene and releasing the expression of its product, the anti-apoptotic factor ARH3.

66 An open question is how these regulations in the lipid metabolism contribute to T1D 67 development. Here, we hypothesize that downregulations of triacylglycerols (in both 68 plasma and islets) and phosphatidylcholines (in plasma) have a role in β-cell death. To for test this hypothesis, we first analyzed lipidomics and proteomics data from human test this hypothesis, we first analyzed lipidomics and proteomics data from human 70 plasma and islets to determine possible regulatory mechanisms of these lipid classes. 71 We also performed experiments in MIN6 insulin-producing cells and analyzed single-cell 72 transcriptomic data to study the downstream consequences of triacylglycerol and 73 phosphatidylcholine downregulation in T1D development. Our data show a mechanism 74 by which lipids accelerate T1D development.

76 **Material and Methods**

77 *Data from a longitudinal cohort of individuals at high risk of developing T1D*

78 *TEDDY Study and lipidomics dataset*. Six clinical research centers - three in the USA 79 (Colorado, Georgia/Florida, Washington State), and three in Europe (Finland, Germany, 80 and Sweden) participated in a population-based HLA screening of newborns between 81 September 1, 2004 and February 28, 2010 21,22 . The HLA high-risk genotypes identified 82 from the general population (89%) and for infants with a first-degree relative with T1D 83 were previously described²³. Children enrolled ($n=8.676$) were prospectively followed 84 from three months of age to 15 years with study visits that include a blood draw every 85 three months until four years and every three or six months thereafter depending on 86 autoantibody positivity. A nested-matched case-control study was conducted through 87 risk-set sampling using metadata and autoantibody sample results as of May 31, 2012, 88 as previously detailed²⁴. Additional matching by the clinical center, sex, and family 89 history of T1D (general population or first-degree relative) were included as criteria in 90 the selection of controls. The sample selection was determined by the Data 91 Coordinating Center (University of South Florida Health Informatics Institute, Tampa, FL) 92 without the lab knowing the case-control status. The characteristics of the donors are 93 listed in **Supplemental Table 1**. Plasma lipidomics data were reanalyzed from the 94 datasets described in previous publications²⁵⁻²⁷. The effect of sample analysis order on 95 quantified lipidomics data was removed by applying Systematic Error Removal using 96 Random Forest (SERRF)²⁸. All missing values were replaced with "NA", and data were 97 log2 transformed. For each time point and lipid combination, a paired *t*-test, accounting 98 for case-control pairs, was conducted, and a Benjamini-Hochberg false-discovery rate 99 correction was applied to the resulting p-values²⁹.

100 *GC-MS analysis*

101 Human islets treated with 50 U/mL human IL-1β + 1000 U/mL human IFN-γ (cytokine 102 cocktail 1 or "CT1") for 24 h were collected as previously described³⁰. The Pacific cocktail 1 or "CT1") for 24 h were collected as previously described³⁰. The Pacific 103 Northwest National Laboratory institutional review board deemed the project to not be 104 human subject research and waived full ethical review. The characteristics of the donors 105 are listed in **Supplemental Table 2**. The data from this experiment were subsequently 106 integrated with proteomics and lipidomics data published elsewhere^{16,30}. Samples from 107 either these human islets or MIN6 cells treated as described above were submitted to 108 simultaneous metabolite, protein, and lipid extraction (MPLEx) 31 . Metabolites were 109 treated with 30 mg/mL methoxyamine in pyridine for 90 min at 37 °C with shaking, and 110 derivatized with N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) (Sigma-Aldrich) 111 with 1% trimethylchlorosilane (TMCS) (Sigma-Aldrich) at 37 °C with shaking for 30 112 min³². Derivatized metabolites were analyzed using an Agilent GC 7890A equipped with 113 an HP-5 MS column (30 m x 0.25 mm x 0.25 µm; Agilent Technologies, Santa Clara, 114 CA) and coupled with a single quadrupole MSD 5975C (Agilent Technologies). Samples 115 were injected into a splitless port set at 250°C with an initial oven temperature of 60 °C. 116 After 1 min the temperature was increased to 325°C at a rate of 10°C/min, and finished 117 with a 5-min hold at 325 °C. The data files were calibrated with external calibration of 118 fatty acid methyl ester and converted to retention time indexes relative to the elution of 119 the fatty acid methyl esters. Molecules were identified by matching experimental 120 retention indices and/or mass spectra to an in-house augmented version of FiehnLib, 121 NIST20, Wiley 11th edition, and MS-DIAL databases 122 (https://systemsomicslab.github.io/compms/index.html)^{33,34}. Significant differences in 123 metabolite relative abundances were determined by Student's *t*-test. The central carbon 124 metabolism pathway was plotted along with each metabolite relative abundance using 125 Vanted 35 .

126 *Cell culture*

127 MIN6 cells were maintained at 37 \degree C in a 5% CO₂ atmosphere in DMEM containing 4.5 128 g/L each of D-glucose and L-glutamine, 10% fetal bovine serum, 100 units/mL penicillin, 129 100 μg/mL streptomycin, and 50 μM 2-mercaptoethanol. For cell assay experiments,
130 cells were treated at 80% confluency with a cytokine cocktail (CT2: 100 ng/mL mouse cells were treated at 80% confluency with a cytokine cocktail (CT2: 100 ng/mL mouse 131 IFN-γ: R&D, cat#485-MI-100, 10 ng/mL mouse TNF-α: R&D, Cat#410-MT-010, and 5
132 ng/mL mouse IL-1β: R&D, cat #401-ML-005) for 24 h. Cells were treated concurrently 132 ng/mL mouse IL-1β: R&D, cat #401-ML-005) for 24 h. Cells were treated concurrently
133 with various concentrations of palmitate (Cayman, CAS#10006627), 10 μM NAMPT with various concentrations of palmitate (Cayman, CAS#10006627), 10 µM NAMPT 134 inhibitor FK866 (MCE, Cat. No.: HY-50876), 200 µM hexokinase inhibitor lonidamine 135 (Tocris, Cat. No. 1646), or 100 µM nicotinamide riboside (NR) (MCE, HY-123033A). The 136 concentration of NAMPT inhibitor, hexokinase inhibitor, and NR was determined by a 137 dose-response curve, and the concentration with maximum effect was chosen. 138 Palmitate stock was prepared in ethanol and diluted in 0.5% delipidated bovine serum 139 albumin to keep it in solution.

140 *Proteomics analysis*

141 MIN6 cells were lysed in 50 mM Tris-HCl containing 8 M urea and 10 mM dithiothreitol 142 and incubated for 1 h at 37 °C with shaking at 800 rpm. Iodoacetamide was added to a 143 final concentration of 40 mM from a 400-mM stock, and the sample was incubated for 1 144 h in the dark at 21 °C. The reaction mixture was diluted 8-fold with 50 mM Tris-HCl, and 145 1 M CaCl₂ was added to a final concentration of 1 mM. Proteins were digested 146 overnight at room temperature using sequencing-grade trypsin (Promega) at an 147 enzyme-to-protein ratio of 1:50. Digested peptides were desalted by solid-extraction in 148 C18 cartridges (Discovery, 50 mg, Sulpelco) following manufacturer recommendations, 149 and dried in a vacuum centrifuge. Peptides were analyzed using a Waters NanoAquity 150 UPLC system coupled with a Q-Exactive mass spectrometer, as previously described³⁶. 151 The data were processed with MaxQuant software $(v.1.5.5.)^{37}$ using the mouse

152 reference proteome database from UniProt Knowledge Base (downloaded on 153 08/31/2023). Protein N-terminal acetylation and oxidation of methionine were set as 154 variable modifications, while cysteine carbamidomethylation was set as a fixed 155 modification. The software's default mass shift tolerance was used. Statistical analysis 156 and heatmap were done using Perseus³⁸. MaxLFQ intensity was used to quantify 157 protein, being log2 transformed, median normalized, and having the missing values 158 were imputed with Gaussian distribution³⁹. Student's *t*-test was used to determine 159 statistically different proteins. Functional-enrichment analysis was done for the 160 statistically significant proteins using DAVID⁴⁰, using all the predicted mouse genes as 161 the background.

162 *Apoptosis, NAD, and ATP assays*

163 Apoptosis, NAD, and ATP levels were measured with Caspase-Glo, NAD/NADH-Glo, 164 and CellTiter-Glo® 2.0, respectively, following the manufacturer-provided protocols 165 (Promega Cat# G8092, G9071, and G9242). MIN6 cells were treated with palmitate, 166 FK866, lonidamine, or NR, and CT2 for 24 h. The appropriate amount of the assay 167 reagent was added to the wells. The contents were gently mixed for 30 s and 168 luminescence was read for 3 h every 30-min interval using a plate reader (Synergy HT, 169 BioTek). The time point with the highest signal was selected for analysis. All statistical 170 analysis and data visualization were performed using GraphPad Prism 9 (Version 9.4.1 171 (458)).

172 *Single cell RNA seq analysis*

173 The raw single-cell RNA-seq data files (FASTQ, 10X Genomics) of human islets⁴¹ were 174 downloaded from the Human Pancreas Analysis Program (HPAP) data portal 175 (https://hpap.pmacs.upenn.edu/) and processed with Cell Ranger (v6.1.2). The clinical 176 characteristics of the donors are listed in **Supplementary Table 3**. Data were 177 processed following 10X Genomics recommendations for quality control, read alignment 178 to the reference genome (hg38), barcode processing, and molecule counting. Initial 179 clustering was performed using Seurat software (v4.1.1), followed by decontamination 180 of background mRNA using SoupX (v1.6.1); key genes (*INS*, *GCG*, *SST*, *TTR*, *IAPP*, 181 *PYY*, *KRT19*, *TPH1*) representing the major cell types were identified in the initial 182 clustering. The adjusted gene expression counts were further processed in Seurat for 183 additional filtering. Potential doublets were identified and removed using scDblFinder 184 (v3.16). Cells were filtered based on the following criteria: nFeature_RNA > 1,000 and < 185 9,000, mitochondrial gene percentage < 15%, and nCount < 100,000. Following the 186 steps outlined above, we obtained 91,047 single cells for downstream analysis. 187 Normalization of counts was done using the R package scTransform, which adjusts for 188 library size variations per cell. Mitochondrial gene variation was also regressed out, as it 189 indicates cell state. We selected the top 3,000 variable genes to perform principal 190 component analysis (PCA). Data integration was conducted using Harmony (v0.1.1) 191 with the top 50 PCA components, accounting for each sample and reagent kit batches 192 as confounding factors. The integrated components were used to construct a Uniform 193 Manifold Approximation and Projection (UMAP) embedding of the 91,047 cells. Finally, 194 cell types were annotated with scSorter (v0.0.2) based on known marker genes.

- 195 ExcelChIP-Seq data visualization was performed using IGV software.
- 196

197 **Results**

198 *Pro-inflammatory cytokines induce the release of palmitate in human islets*

199 We have previously shown that triacylglycerols were consistently downregulated in 3 200 insulitis models: islets from NOD mice in the prediabetic stage, and EndoC-βH1 cells and human islets treated with a cocktail of pro-inflammatory cytokines (CT1: 50 U/mL 202 IL-1β and 1000 U/mL IFN-γ)¹⁶. To further study this phenotype, we analyzed our 203 previously published proteomics dataset from the same human islets 30 and found that 204 endothelial lipase LIPG was increased 1.4-fold with CT1 treatment (**Fig. 1A**), suggesting 205 a possible mechanism. A gas chromatography-mass spectrometry analysis of the same 206 human islets treated with CT1 showed that palmitate was increased 1.7-fold with CT1 207 treatment (**Fig. 1B**). These data show that CT1 induces the digestion of TGs into free 208 fatty acids (FFAs).

209 *Increase of free fatty acid levels in plasma from donors with islet autoimmunity*

210 We investigated if TG digestion and fatty acid release also occurs *in vivo*, during T1D 211 development. As LIPG is a major plasma lipoprotein lipase, we search these signatures 212 on the plasma lipidomics data of the nested case-control 1 study (NCC1) from The 213 Environmental Determinants of Diabetes in the Young (TEDDY) study (**Supplemental** 214 **Table 4**). In TEDDY NCC1, samples were collected every 3 months from individuals 215 carrying the high-risk HLA alleles from birth until the age of 6 years. We included data 216 from all 94 children who progressed to clinical T1D and from their matched controls. The 217 lipidomics data showed a decrease in the levels of 18 of the 127 phosphatidylcholine 218 species (14%) and 14 of the 100 triacylglycerol species (14%) 3 months post-219 seroconversion (**Fig. 2A**). The phosphatidylcholine and triacylglycerol intermediate 220 cleavage products lysophosphatidylcholines and diacylglycerols, respectively, displayed 221 a downregulation trend with 3 out of their 32 species (10%) significantly reduced (**Fig.** 222 **2B**). Among the FFAs, 2 and 4 of their 31 species (19%) were upregulated at the time of 223 and 3 months post-seroconversion, respectively (**Fig. 2C**). The downstream products 224 from FFAs, acyl-carnitines, had 3 and 7 of their 17 species (59%) upregulated at the 225 time of and 3 months post-seroconversion, respectively (**Fig. 2C**). This suggests that 226 the extent of fatty acid release is higher than the one observed based on FFA 227 abundance alone.

228 We also examined the abundance of key lipoprotein subunits and lipases in TEDDY 229 NCC1 proteomics data¹⁵. Apolipoprotein ApoA1 was upregulated pre-seroconversion, 230 whereas ApoA2, ApoB, ApoC1, ApoC2 and ApoC3 were downregulated post-231 seroconversion (**Fig. 2D**). Regarding lipases, the lipoprotein lipase LPL and the hepatic 232 lipase LIPC had similar abundances pre- and post-seroconversion compared to the 233 control group (**Fig. 2D**). LIPG was not detected in the analysis.

234 Overall, these data suggest a digestion of phosphatidylcholines and triacylglycerols, 235 leading to the release of FFAs. These changes are accompanied by reduction in 236 multiple lipoprotein subunits.

237 *Palmitate enhances pro-inflammatory cytokine-mediated apoptosis.*

238 To study if the FFAs have a role in β-cell death, we measured apoptosis in MIN6 cells
239 treated with a cytokine cocktail (CT2: 100 ng/mL IFN-γ, 10 ng/mL TNF-α, and 5 ng/mL 239 treated with a cytokine cocktail (CT2: 100 ng/mL IFN-y, 10 ng/mL TNF- α , and 5 ng/mL 240 IL-1 β) for 24 h in combination with a variety of fatty acids at 400 µM: oleate (18:1), 240 IL-1β) for 24 h in combination with a variety of fatty acids at 400 μM: oleate (18:1),
241 stearate (18:0), palmitate (16:0), arachidonate (20:4), linoleate (18:2), arachidonate 242 docosahexaenoate (22:6) and eicosapentaenoate (20:5). While stearate, palmitate and 243 linoleate had minimal to no effect on MIN6 cells without cytokines, they synergistically 244 enhanced the cytokine-mediated apoptosis (**Fig. 3A**). Conversely, arachidonate and 245 eicosapentaenoate reduced apoptosis in both cells treated or not treated with CT2 (**Fig.** 246 **3A**). As palmitate had the strongest effect and was also released by LIPG in islets, it 247 was chosen for the remaining experiments. We treated MIN6 cells with various 248 concentrations of palmitate (50-800 μM) in combination with CT2 for 24 h and measured
249 apoptosis. The palmitate treatment itself had no effect on β-cell apoptosis up to 400 μM, 249 apoptosis. The palmitate treatment itself had no effect on β-cell apoptosis up to 400 μM,
250 but concentrations as low as 200 μM significantly enhanced the apoptosis induced by 250 but concentrations as low as 200 μ M significantly enhanced the apoptosis induced by 251 CT2 (Fig. 3B). These results showed that FFAs increase cytokine-mediated apoptosis. 251 CT2 (**Fig. 3B**). These results showed that FFAs increase cytokine-mediated apoptosis.

252 *NAMPT as a regulator of FFA-enhanced cytokine-mediated apoptosis*

253 To identify possible mechanisms of FFA enhancement of cytokine-mediated apoptosis, 254 we performed a proteomics analysis of MIN6 cells treated with $CT2 + 400 \mu$ M palmitate,
255 leading to the identification of 6049 proteins (**Supplemental Table 5**). The CT2 255 leading to the identification of 6049 proteins (**Supplemental Table 5**). The CT2 256 treatment itself regulated the levels of 631 proteins (86 upregulated and 545 257 downregulated), while the palmitate treatment itself regulated the levels of 262 proteins 258 (10 upregulated and 252 downregulated) (**Supplemental Table 6-7**). The CT2 + 259 palmitate vs. CT2 comparison resulted in abundance changes of 261 proteins (45 and 260 216 proteins upregulated and downregulated, respectively) (**Fig. 3C, Supplemental** 261 **Table 8**). A functional-enrichment analysis of this comparison identified 48 pathways to 262 be significantly enriched among the regulated proteins (**Fig. 3D**). This included 263 metabolic pathways (e.g. oxidative phosphorylation, amino sugar and nucleotide sugar 264 metabolism, insulin signaling pathway), cell-death pathways (e.g. necroptosis, NOD-like 265 receptor signaling pathway) and immune response pathways (e.g. PD-L1 expression, 266 human cytomegalovirus infection).

267 We next investigated possible mechanisms of apoptosis enhancement by the CT2 + 268 palmitate treatment. In the proteomics analysis, the NOD-like receptor signaling 269 pathway was the one directly involved in apoptosis among those regulated when 270 comparing CT2 + palmitate vs. CT2 conditions (**Fig. 3D**). One standout member of this 271 pathway was nicotinamide phosphoribosyltransferase, NAMPT, whose levels were 272 upregulated 4.5-fold in cells treated with CT2 and diminished by 0.6-fold following 273 addition of palmitate to the CT2 treatment (**Fig. 4A**). NAMPT is also the rate-limiting 274 enzyme of the intracellular nicotinamide adenosine dinucleotide (NAD) salvage 275 biosynthesis pathway. To test the role of NAMPT depletion in enhancing CT2-mediated 276 apoptosis, we treated MIN6 cells with its inhibitor FK866 in combination with CT2. The 277 inhibition of NAMPT induced a phenotype similar to that of palmitate-induced 278 enhancement of CT2-mediated apoptosis, which was abolished by supplementing the 279 cells with nicotinamide riboside (NR) (**Fig. 4B**), a metabolite downstream from NAMPT 280 in the NAD salvage pathway. We next measured the levels of NAD in FK866-treated 281 cells, which confirmed that FK866 causes depletion of NAD and that its production was 282 rescued by the addition of NR **(Fig. 4C)**. We treated MIN6 cells with CT2 + palmitate in 283 combination with NR and measured both apoptosis and NAD levels. The NR 284 supplementation failed to rescue both the apoptosis enhancement by palmitate (**Fig.** 285 **4D**) and the recovery of cellular NAD levels (**Fig. 4E**). These data show that palmitate 286 enhances cytokine-mediated apoptosis via downregulation of NAMPT and depletion of 287 NAD levels. However, NR supplementation fails to rescue the cells from apoptosis, 288 suggesting that additional factors are involved.

289 *Deregulation of the central carbon metabolism by cytokines + palmitate reduces* 290 *cellular ATP levels*

291 We next investigated possible additional factors that impair NR from rescuing cells from 292 the cytokine-mediated apoptosis enhanced by palmitate. The insulin receptor signaling 293 pathway, which regulates glycolysis, was one of the pathways identified as 294 downregulated in the proteomics analysis comparing the CT2 + palmitate vs. CT2 295 conditions (**Fig. 3C**). Eight proteins of this pathway were downregulated, including the 296 glycolysis rate-limiting enzyme hexokinase 1 (HK1) (**Fig. 5A**). In MIN6 cells, the CT2 297 treatment alone decreased the level of HK1 by 1.6-fold, but the combination of CT2 + 298 palmitate reduced the levels of HK1 by 33% (**Fig. 5B**). To investigate possible 299 consequences of this regulation on central carbon metabolism, we performed a GC-MS 300 metabolomics analysis of MIN6 cells treated with the combination of CT2 + palmitate for 301 8 h. The palmitate treatment alone only reduced the levels of lactate (**Fig. 5C**), while 302 CT2 treatment alone induced a trend for increasing the glycolytic activity with elevated 303 but not significant pyruvate concentration (**Fig. 5C**). The combined CT2 + palmitate 304 treatment led to an increase in phosphoenolpyruvate and reduction in lactate levels 305 compared to the control (**Fig. 5C**). Downstream, there was an increase in the late TCA 306 cycle metabolites α -ketoglutarate, malate and fumarate comparing the CT2 + palmitate 307 vs. the CT2 alone conditions (Fig. 5C). There is an increase in glutamate and glutamine vs. the CT2 alone conditions (**Fig. 5C**). There is an increase in glutamate and glutamine 308 (**Fig. 5C**), suggesting an overflow from the central carbon metabolism towards the 309 amino acid metabolism.

310 Next, we measured the levels of ATP to determine how these changes in the central 311 carbon metabolism affect energy production. The ATP level was reduced by 8% in cells 312 treated solely with palmitate and by 20% in cells treated with CT2. The CT2 + palmitate 313 treatment reduced ATP by 38% (**Fig. 5E**), showing that cellular energy production is 314 compromised. To test the role of HK1 in the regulation of the CT2 + palmitate enhanced 315 apoptosis, we treated the cells with the HK1 inhibitor lonidamine. The treatment 316 enhanced the CT2-mediated apoptosis in MIN6 by 1.25-fold (**Fig. 5D**). However, a 317 similar increase was also observed in cells not treated with cytokines (1.4-fold increase) 318 (**Fig. 5D**), suggesting that HK1 is not responsible for the enhancement of cytokine-319 mediated apoptosis by palmitate. These results show that downregulation of HK1 is not 320 responsible for enhancement of cytokine-mediated apoptosis by palmitate. However, 321 FFA in combination with cytokines affected central carbon metabolism and ATP 322 production, which might contribute to the depletion of NAD as the salvage pathway 323 requires ATP.

³²⁴*Downregulation of the NAD salvage pathway and central carbon metabolism in* ^β 325 *cells during T1D development*

326 To study if the NAD salvage pathway and central carbon metabolism regulation may 327 occur *in vivo* during T1D development, we analyzed the islet single cell RNA seq data 328 \pm from human donors in different stages of T1D development⁴². These data contained 329 quantitative sequencing information from 12,660 β cells, including 4,710 from non-
330 diabetic donors, 4,156 from donors with single islet autoantibodies, 2,521 from donors 330 diabetic donors, 4,156 from donors with single islet autoantibodies, 2,521 from donors 331 with multiple islet autoantibodies, and 1,273 from donors with T1D. In the NAD salvage 332 pathway, we found that NAMPT expression is higher in β cells of non-diabetic donors,
333 and significantly reduced in individuals with single or multiple autoantibodies (Fig. 6A). and significantly reduced in individuals with single or multiple autoantibodies (**Fig. 6A**). 334 In central carbon metabolism, there is a downregulation of 12 of the 20 detected 335 transcripts of the glycolytic pathway in β cells in individuals with one or multiple islet 336 autoantibodies (**Fig. 6B**). After the onset of the disease, the levels of the glycolytic autoantibodies (Fig. 6B). After the onset of the disease, the levels of the glycolytic 337 enzymes are slightly higher with the transcripts of 3 enzymes upregulated (**Fig. 6B**). A 338 similar pattern is observed in the TCA cycle, with the expression of 12 enzymes reduced 339 in individuals positive for one or multiple autoantibodies, and 4 enzymes increased after 340 the onset of the disease (**Fig. 6C**). These results show that the expression of the

341 components of the NAD salvage pathway, glycolysis, and TCA cycle are downregulated 342 in β cells during T1D development, supporting our *in vitro* findings.

343

344

345

346 **Discussion**

347 Our current and previous data¹⁶ show that CT1 reduced the levels of triacylglycerols, 348 which was associated to LIPG upregulation and their digestion into FFAs. In the TEDDY 349 plasma lipidomics data, there is a similar pattern with decrease in triacylglycerols and 350 phosphatidylcholines and an increase in FFAs at 3 months post-seroconversion. 351 Although some of the increases in FFA levels are moderate, we found that 352 concentrations as low as 200 μ M of palmitate enhances cytokine-mediated apoptosis.
353 Considering that the basal levels of palmitate in plasma are around 145 μ M⁴⁴, even Considering that the basal levels of palmitate in plasma are around 145 μ M⁴⁴, even
354 small changes in FFA concentration might have a deleterious effect when combined small changes in FFA concentration might have a deleterious effect when combined 355 with the local pro-inflammatory cytokines present during insulitis in a chronic disease.

356 Regarding specific plasma lipoproteins, ApoA1 and ApoA2 (which were regulated in the 357 proteomics analysis) are major components of HDL and chylomicrons⁴⁵, but LIPG being 358 an HDL lipase⁴⁶, making more likely that high-density lipoprotein (HDL) is involved in the 359 process. HDL is also the particle richest in phospholipids⁴⁵, and is a possible source of 360 the phosphatidylcholines digested after seroconversion. Likewise, HDL decreases after 361 seroconversion but returns to basal levels after T1D diagnosis, suggesting a temporary 362 regulation⁴⁷. ApoB was also reduced after seroconversion in our proteomics analysis. 363 This protein has two major isoforms, the full-length ApoB-100, enriched in low-density 364 lipoprotein (LDL) and very low-density lipoprotein (VLDL), and ApoB-48, enriched in 365 chylomicrons⁴⁵. Unfortunately, our bottom-up proteomics analysis does not distinguish 366 between the two isoforms. Considering that all three particles are rich in 367 triacylglycerols⁴⁵, each could be the source of the triacylglycerols that are digested after 368 seroconversion. During islet autoimmunity, LDL levels remain unaltered but are 369 increased later⁴⁷.

370 Regarding lipases involved in the fatty acid release, LIPG is a cell surface lipoprotein 371 lipase that digests lipids from HDL and facilitates the uptake of fatty acids by cells⁴³. 372 LIPG also helps to dock and internalize HDL, LDL, VLDL particles by cells⁴³. LIPC is 373 less likely to be involved as its regulation is mainly via transcription⁴⁸ and its levels in the 374 proteomics analysis remained unaltered. LPL protein levels also remained unaltered, 375 but its activity might be enhanced by the observed reduction in its inhibitors ApoC1 and 376 ApoC3. Low ApoC1 is associated with progression to T1D before the age of 5 years⁴⁹. 377 There is a similar pattern of ApoC1 in the TEDDY NCC1, where its reduction was 378 associate with the development of T1D by the age of 6 years¹⁵. LIPG and LPL might 379 work sequentially to digest triacylglycerols and phosphatidylcholines, as LIPG mainly 380 cleaves fatty acyl groups at the *sn-1* position into diacylglycerols and 381 lysophosphatidylcholines⁴³. These intermediates largely remained unaltered in the 382 process, suggesting that they are being cleaved by the action of additional lipase(s).

- 383 Both LIPG and LPL play relevant roles in inflammation. In macrophages, LIPG mediates 384 toll-like receptors 3 and 4 signaling by repressing and inducing the expression of anti-385 and pro-inflammatory genes, respectively⁴³. LPL enhances interferon-γ-induced pro-
386 inflammatory signaling in endothelial cells⁵⁰. Our results show that released FFAs inflammatory signaling in endothelial cells⁵⁰. Our results show that released FFAs 387 enhance cytokine-mediated apoptosis in MIN6 cells, which involves the depletion of 388 NAD. Pro-inflammatory cytokines induce an upregulation of the NAD *de novo* synthesis 389 . pathway in human islets⁵¹. This pathway promotes an efficient inflammatory response 390 by fueling the cell with NAD^{52} , and might provide the NAD needed during insulitis. Our 391 data show that the combination of CT2 + palmitate inhibits the NAD salvage pathway, 392 depleting cellular NAD. In the body, the *de novo* synthesis pathway is particularly active 393 in the liver, while other tissues rely mostly on the salvage pathway⁵³. This agrees with 394 the strong impact we observed in cells treated with cytokines + palmitate. In 395 hepatocytes, palmitate downregulates the expression of NAMPT, leading to apoptosis⁵⁴. 396 However, in contrast to our observations, the hepatocyte apoptosis is reversed by the 397 addition of nicotinamide mononucleotide, a metabolite downstream from NAMPT in the 398 NAD salvage pathway⁵⁴. In our experimental condition, the cells are not rescued with 399 NR, another metabolite downstream from NAMPT in the NAD salvage pathway.
- 400 We found that the combination of FFAs with cytokines induced major changes cellular 401 central carbon metabolism. The cells treated with cytokines + palmitate had an 402 unproductive accumulation of various glycolytic and TCA cycle intermediates, leading to 403 reduction in cellular ATP levels. This might explain the inability to rescue the cells with 404 NR, as both enzymes of the salvage pathway, NAMPT and NMNAT, require ATP to 405 catalyze their reactions. Therefore, the deregulation in central carbon metabolism 406 further aggravates the impairment in the NAD salvage pathway⁵⁵. Overall, our data 407 show that inflammation leads to a release in FFAs, which aggravates cytokine-mediated 408 apoptosis. This process was associated with the development of T1D at a young age 409 (<6 years). The mechanism involves depletion of cellular NAD levels by impairing its 410 recycling via the salvage pathway, which is further aggravated by deregulation of central 411 carbon metabolism leading to reduced ATP production.
- 412

413 **Competing interests**

- 414 The authors declare that they have no competing interests.
- 415

416 **Acknowledgments**

417 Part of the work was performed in the Environmental Molecular Sciences Laboratory, a 418 U.S. DOE national scientific user facility at Pacific Northwest National Laboratory 419 (PNNL) in Richland, WA. Battelle operates PNNL for the DOE under contract DE-AC05- 420 76RLO01830. This work was supported by the Catalyst Award from the Human Islet 421 Research Network (HIRN) (to E.S.N) (via U24 DK104162) and by National Institutes of 422 Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 423 grants R01 DK138335 (to E.S.N., M.R., B.J.M.W.R and T.O.M.), U01 DK127505 (to 424 E.S.N.), U01 DK127786 (to R.G.M, D.L.E, B.J.M.W.R and T.O.M.), R01 DK060581 (to 425 R.G.M.), R01 DK105588 (to R.G.M.) The TEDDY Study is funded by U01 DK63829, 426 U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 427 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 428 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, UC4 429 DK112243, UC4 DK117483, U01 DK124166, U01 DK128847, and Contract No. 430 HHSN267200700014C from the NIDDK, National Institute of Allergy and Infectious 431 Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and 432 Human Development (NICHD), National Institute of Environmental Health Sciences 433 (NIEHS), Centers for Disease Control and Prevention (CDC), and JDRF. This work is 434 supported in part by the NIH/NCATS Clinical and Translational Science Awards to the 435 University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR002535). 436 The content is solely the responsibility of the authors and does not necessarily 437 represent the official views of the National Institutes of Health.

438

439 **Data availability**

440 The TEDDY lipidomics data are available at the Metabolomics Workbench repository 441 under project ID PR000950 and doi 10.21228/M8WM4P. The GC-MS data were 442 uploaded into the Open Science Framework under accession number 86u3m 443 (https://osf.io/86u3m/). The proteomics data were deposited into the MassIVE 444 repository, a member of the ProteomeXchange, under accession number 445 MSV000095733.

447 References

- 448 1. Beran, D.*, et al.* A plan to improve global type 1 diabetes epidemiology data. 449 *Lancet Diabetes Endocrinol* **11**, 154-155 (2023).
- 450 2. Gregory, G.A.*, et al.* Global incidence, prevalence, and mortality of type 1 451 diabetes in 2021 with projection to 2040: a modelling study. *Lancet Diabetes* 452 *Endocrinol* **10**, 741-760 (2022).
- 453 3. Huo, L., Harding, J.L., Peeters, A., Shaw, J.E. & Magliano, D.J. Life expectancy 454 of type 1 diabetic patients during 1997-2010: a national Australian registry-based 455 cohort study. *Diabetologia* **59**, 1177-1185 (2016).
- 456 4. DiMeglio, L.A., Evans-Molina, C. & Oram, R.A. Type 1 diabetes. *Lancet* **391**, 457 2449-2462 (2018).
- 458 5. Atkinson, M.A., Eisenbarth, G.S. & Michels, A.W. Type 1 diabetes. *Lancet* **383**, 459 69-82 (2014).
- 460 6. Veijola, R.*, et al.* HLA-DQB1-defined genetic susceptibility, beta cell 461 autoimmunity, and metabolic characteristics in familial and nonfamilial insulin-462 dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. 463 *J Clin Invest* **98**, 2489-2495 (1996).
- 464 7. Baisch, J.M.*, et al.* Analysis of HLA-DQ genotypes and susceptibility in insulin-465 dependent diabetes mellitus. *N Engl J Med* **322**, 1836-1841 (1990).
- 466 8. Sanjeevi, C.B.*, et al.* Polymorphic amino acid variations in HLA-DQ are 467 associated with systematic physical property changes and occurrence of IDDM. 468 Members of the Swedish Childhood Diabetes Study. *Diabetes* **44**, 125-131 469 (1995).
- 470 9. Rewers, M. & Ludvigsson, J. Environmental risk factors for type 1 diabetes. 471 *Lancet* **387**, 2340-2348 (2016).
- 472 10. Lamichhane, S.*, et al.* Dynamics of Plasma Lipidome in Progression to Islet 473 Autoimmunity and Type 1 Diabetes - Type 1 Diabetes Prediction and Prevention 474 Study (DIPP). *Sci Rep* **8**, 10635 (2018).
- 475 11. Ferrara-Cook, C.*, et al.* Excess BMI Accelerates Islet Autoimmunity in Older 476 Children and Adolescents. *Diabetes Care* **43**, 580-587 (2020).
- 477 12. Lamichhane, S.*, et al.* Dysregulation of secondary bile acid metabolism precedes 478 islet autoimmunity and type 1 diabetes. *Cell Rep Med* **3**, 100762 (2022).
- 479 13. Nelson, A.J.*, et al.* Lipid mediators and biomarkers associated with type 1 480 diabetes development. *JCI Insight* **5**(2020).
- 481 14. Diaz Ludovico, I.*, et al.* Fatty acid-mediated signaling as a target for developing 482 type 1 diabetes therapies. *Expert Opin Ther Targets* **27**, 793-806 (2023).
- 483 15. Nakayasu, E.S.*, et al.* Plasma protein biomarkers predict the development of 484 persistent autoantibodies and type 1 diabetes 6 months prior to the onset of 485 autoimmunity. *Cell Rep Med* **4**, 101093 (2023).
- 486 16. Sarkar, S.*, et al.* Regulation of beta-cell death by ADP-ribosylhydrolase ARH3 via 487 lipid signaling in insulitis. *Cell Commun Signal* **22**, 141 (2024).
- 488 17. Yuan, X.*, et al.* Functional and metabolic alterations of gut microbiota in children 489 with new-onset type 1 diabetes. *Nat Commun* **13**, 6356 (2022).
- 490 18. Bi, X.*, et al.* omega-3 polyunsaturated fatty acids ameliorate type 1 diabetes and 491 autoimmunity. *J Clin Invest* **127**, 1757-1771 (2017).

- 492 19. Lo Conte, M.*, et al.* A diet enriched in omega-3 PUFA and inulin prevents type 1 493 diabetes by restoring gut barrier integrity and immune homeostasis in NOD mice. 494 *Front Immunol* **13**, 1089987 (2022).
- 495 20. Norris, J.M.*, et al.* Omega-3 polyunsaturated fatty acid intake and islet 496 autoimmunity in children at increased risk for type 1 diabetes. *JAMA* **298**, 1420- 497 1428 (2007).
- 498 21. Group, T.S. The Environmental Determinants of Diabetes in the Young (TEDDY) 499 Study. *Ann N Y Acad Sci* **1150**, 1-13 (2008).
- 500 22. Johnson, S.B.*, et al.* The Environmental Determinants of Diabetes in the Young 501 (TEDDY) study: predictors of early study withdrawal among participants with no 502 family history of type 1 diabetes. *Pediatr Diabetes* **12**, 165-171 (2011).
- 503 23. Hagopian, W.A.*, et al.* The Environmental Determinants of Diabetes in the Young 504 (TEDDY): genetic criteria and international diabetes risk screening of 421 000 505 infants. *Pediatr Diabetes* **12**, 733-743 (2011).
- 506 24. Lee, H.S.*, et al.* Biomarker discovery study design for type 1 diabetes in The 507 Environmental Determinants of Diabetes in the Young (TEDDY) study. *Diabetes* 508 *Metab Res Rev* **30**, 424-434 (2014).
- 509 25. Li, Q.*, et al.* Plasma Metabolome and Circulating Vitamins Stratified Onset Age of 510 an Initial Islet Autoantibody and Progression to Type 1 Diabetes: The TEDDY 511 Study. *Diabetes* **70**, 282-292 (2021).
- 512 26. Li, Q.*, et al.* Longitudinal Metabolome-Wide Signals Prior to the Appearance of a 513 First Islet Autoantibody in Children Participating in the TEDDY Study. *Diabetes* 514 **69**, 465-476 (2020).
- 515 27. Webb-Robertson, B.M.*, et al.* Prediction of the development of islet 516 autoantibodies through integration of environmental, genetic, and metabolic 517 markers. *J Diabetes* **13**, 143-153 (2021).
- 518 28. Fan, S.*, et al.* Systematic Error Removal Using Random Forest for Normalizing 519 Large-Scale Untargeted Lipidomics Data. *Anal Chem* **91**, 3590-3596 (2019).
- 520 29. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical 521 and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical* 522 *Society: Series B (Methodological)* **57**, 289-300 (1995).
- 523 30. Nakayasu, E.S.*, et al.* Comprehensive Proteomics Analysis of Stressed Human 524 Islets Identifies GDF15 as a Target for Type 1 Diabetes Intervention. *Cell Metab* 525 **31**, 363-374 e366 (2020).
- 526 31. Nakayasu, E.S.*, et al.* MPLEx: a Robust and Universal Protocol for Single-527 Sample Integrative Proteomic, Metabolomic, and Lipidomic Analyses. *mSystems* 528 **1**(2016).
- 529 32. Kim, Y.M.*, et al.* Salmonella modulates metabolism during growth under 530 conditions that induce expression of virulence genes. *Mol Biosyst* **9**, 1522-1534 531 (2013).
- 532 33. Hiller, K.*, et al.* MetaboliteDetector: comprehensive analysis tool for targeted and 533 nontargeted GC/MS based metabolome analysis. *Anal Chem* **81**, 3429-3439 534 (2009).
- 535 34. Kind, T.*, et al.* FiehnLib: mass spectral and retention index libraries for 536 metabolomics based on quadrupole and time-of-flight gas chromatography/mass 537 spectrometry. *Anal Chem* **81**, 10038-10048 (2009).

- 538 35. Junker, B.H., Klukas, C. & Schreiber, F. VANTED: a system for advanced data 539 analysis and visualization in the context of biological networks. *BMC* 540 *Bioinformatics* **7**, 109 (2006).
- 541 36. Sarkar, S.*, et al.* Regulation of β-cell death by ADP-ribosylhydrolase ARH3 via 542 lipid signaling in insulitis. *Cell Commun Signal* **In press**.
- 543 37. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, 544 individualized p.p.b.-range mass accuracies and proteome-wide protein 545 quantification. *Nat Biotechnol* **26**, 1367-1372 (2008).
- 546 38. Tyanova, S.*, et al.* The Perseus computational platform for comprehensive 547 analysis of (prote)omics data. *Nature Methods* **13**, 731-740 (2016).
- 548 39. Tyanova, S.*, et al.* The Perseus computational platform for comprehensive 549 analysis of (prote)omics data. *Nat Methods* **13**, 731-740 (2016).
- 550 40. Huang da, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative 551 analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 552 44-57 (2009).
- 553 41. Fasolino, M.*, et al.* Single-cell multi-omics analysis of human pancreatic islets 554 reveals novel cellular states in type 1 diabetes. *Nat Metab* **4**, 284-299 (2022).
- 555 42. Kaestner, K.H., Powers, A.C., Naji, A., Consortium, H. & Atkinson, M.A. NIH 556 Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in 557 Type 1 Diabetes: The Human Pancreas Analysis Program (HPAP). *Diabetes* **68**, 558 1394-1402 (2019).
- 559 43. Yu, J.E., Han, S.Y., Wolfson, B. & Zhou, Q. The role of endothelial lipase in lipid 560 metabolism, inflammation, and cancer. *Histol Histopathol* **33**, 1-10 (2018).
- 561 44. Persson, X.M., Blachnio-Zabielska, A.U. & Jensen, M.D. Rapid measurement of 562 plasma free fatty acid concentration and isotopic enrichment using LC/MS. *J* 563 *Lipid Res* **51**, 2761-2765 (2010).
- 564 45. Bhargava, S., de la Puente-Secades, S., Schurgers, L. & Jankowski, J. Lipids 565 and lipoproteins in cardiovascular diseases: a classification. *Trends Endocrinol* 566 *Metab* **33**, 409-423 (2022).
- 567 46. Ishida, T.*, et al.* Endothelial lipase is a major determinant of HDL level. *J Clin* 568 *Invest* **111**, 347-355 (2003).
- 569 47. Aulanni'am, A.*, et al.* The early detection of type 1 diabetes mellitus and latent 570 autoimmune diabetes in adults (LADA) through rapid test reverse-flow 571 immunochromatography for glutamic acid decarboxylase 65 kDa (GAD(65)). 572 *Heliyon* **8**, e08695 (2022).
- 573 48. Rufibach, L.E., Duncan, S.A., Battle, M. & Deeb, S.S. Transcriptional regulation 574 of the human hepatic lipase (LIPC) gene promoter. *J Lipid Res* **47**, 1463-1477 575 (2006).
- 576 49. Hirvonen, M.K.*, et al.* Serum APOC1 levels are decreased in young autoantibody 577 positive children who rapidly progress to type 1 diabetes. *Sci Rep* **13**, 15941 578 (2023).
- 579 50. Kota, R.S., Ramana, C.V., Tenorio, F.A., Enelow, R.I. & Rutledge, J.C. Differential 580 effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-581 gamma-mediated gene expression in human endothelial cells. *J Biol Chem* **280**, 582 31076-31084 (2005).

- 583 51. Garcia-Contreras, M.*, et al.* Metabolomics Study of the Effects of Inflammation, 584 Hypoxia, and High Glucose on Isolated Human Pancreatic Islets. *J Proteome* 585 *Res* **16**, 2294-2306 (2017).
- 586 52. Minhas, P.S.*, et al.* Macrophage de novo NAD(+) synthesis specifies immune 587 function in aging and inflammation. *Nat Immunol* **20**, 50-63 (2019).
- 588 53. Liu, L.*, et al.* Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. *Cell* 589 *Metab* **27**, 1067-1080 e1065 (2018).
- 590 54. Penke, M.*, et al.* Oleate ameliorates palmitate-induced reduction of NAMPT 591 activity and NAD levels in primary human hepatocytes and hepatocarcinoma 592 cells. *Lipids Health Dis* **16**, 191 (2017).
- 593 55. Mehmel, M., Jovanovic, N. & Spitz, U. Nicotinamide Riboside-The Current State 594 of Research and Therapeutic Uses. *Nutrients* **12**(2020).

595

598

599

600 **Figure 1**: Profiles of endothelial lipase LIPG (A) and free palmitate (B) in human islets treated 601 with cytokines IL-1β and IFN-γ (CT1) for 24 h. LIPG was measured by proteomics analysis while
602 palmitate by gas chromatography-mass spectrometry analysis. NoCT – untreated control. ** palmitate by gas chromatography-mass spectrometry analysis. NoCT – untreated control. ** 603 Paired Student's *t*-test p ≤ 0.01.

605 Figure 2

606

607 **Figure 2** – Plasma lipid and lipoprotein profile on during T1D development. Lipid and protein 608 profiles were obtained from lipidomics and proteomics measurements of the TEDDY nested 609 case-control study 1 (NCC1), which comprises of time point sample collections from children up up 610 to the age of 6 years. (A) Heatmap of representative, significant species of phosphatidylcholines 611 (PC) and triacylglycerols (TG). (B) Heatmap of all quantified intermediates of PC and TG, G, 612 lysophosphatidylcholine (LPC) and diacylglycerol (DG), respectively. (C) Heatmap of 613 representative, significant species of PC and TG digestion products, acyl-carnitines (AC) and 614 (free) fatty acids (FA), respectively. Additional abbreviations: ApoA1 – apolipoprotein A1, ApoA2 2 615 – apolipoprotein A2, ApoC1 – apolipoprotein C1, ApoC2 – apolipoprotein C2, ApoC3 – 616 apolipoprotein C3, LIPC – hepatic lipase, LPL – lipoprotein lipase, Pre-SC – pre-seroconversion, 617 Post-SC – post-seroconversion. *Student's *t*-test ≤ 0.05.

618

621

622 **Figure 3.** Enhancement of cytokine-mediated apoptosis by palmitic acid. (**A**) MIN6 cells were 623 treated for 24 h with a cytokine cocktail (CT2: 100 ng/mL IFN-γ, 10 ng/mL TNF-α, and 5 ng/mL
624 IL-1β) in combination with various types of fatty acids at a concentration of 400 μM: oleate, 624 IL-1β) in combination with various types of fatty acids at a concentration of 400 μM: oleate, stearate, palmitate, arachidonate, linoleate, docosahexaenoate, eicosapentaenoate and 626 apoptosis levels measured by caspase 3/7 activity using a luminescent assay. (**B**) The cells 627 were treated with CT2 in combination with various concentrations of palmitate and apoptosis 628 was measured. (**C**) Heatmap of significant proteins comparing CT2 vs. CT2 + 400 μM palmitate.
629 (**D**) Function enrichment analysis of significant proteins comparing CT2 vs. CT2 + palmitate. (D) Function enrichment analysis of significant proteins comparing CT2 vs. CT2 + palmitate. 630 Additional abbreviations: NoCT – no cytokine treatment control, Eth – ethanol vehicle control. 2-

631 way ANOVA, Šídák's multiple comparisons test: *p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 632 0.0001. 0.0001.

633

634 **Figure 4** – Regulation of NAD metabolism in cytokine-mediated apoptosis by palmitate. MIN6 635 cells were treated with cytokine cocktail (CT2: 100 ng/mL IFN- γ , 10 ng/mL TNF- α , and 5 ng/mL
636 IL-18) in combination with 400 µM palmitate. (A) Levels of NAMPT measured by proteomics 636 IL-1β) in combination with 400 µM palmitate. (**A**) Levels of NAMPT measured by proteomics 637 analysis. Levels of apoptosis (measured by caspase 3/7 activity) (**B**) and NAD (**C**) in cells 638 treated with CT2 in combination with 10 µM NAMPT inhibitor FK866 and 100 µM nicotinamide 639 ribose (NR). Levels of apoptosis (measured by caspase 3/7 activity) (**D**) and NAD (**E**) in cells 640 treated with CT2 + 400µM palmitate in combination with 100 µM NR. Additional abbreviations: 641 NoCT – no cytokine treatment control, Eth – ethanol vehicle control. 2-way ANOVA, Šídák's 642 multiple comparisons test: *p \leq 0.05, ** p \leq 0.01, *** p \leq 0.001, **** p \leq 0.0001.

644 **Figure 5** – Regulation of the central carbon metabolism by the cytokine cocktail (CT2: 100 00 645 ng/mL IFN-γ, 10 ng/mL TNF-α, and 5 ng/mL IL-1β) + palmitate. (**A**) Enrichment of palmitate + + 646 CT2-regulated proteins onto the insulin receptor signaling pathway using IPA. (**B**) Hexokinase 1 1 647 HK1 protein level measured by proteomic analysis. Levels of apoptosis (measured by caspase 648 3/7 activity) (**C**) in MIN6 cells treated with CT2 with or without 400 μM palmitate in combination on 649 with 200 µM hexokinase inhibitor lonidamine and 100 µM nicotinamide riboside (NR). (D) Level 650 of various metabolites from the central carbon metabolism measured using GC-MS in MIN6 cell 651 treated with CT2 + 400 µM palmitate. (**E**) Level of ATP measured in MIN6 cell treated with CT2 T2 652 + 400 µM palmitate. Additional abbreviations: NoCT – no cytokine treatment control, Eth – 653 ethanol vehicle control. T-test (**D**), 2-way ANOVA, Šídák's multiple comparisons test (**B**, **C**, & **E**):): 654 $*$ $*$ p \leq 0.01, $**$ p \leq 0.001, $***$ p \leq 0.0001.

655

656 **Figure 6** – Expression of genes from the NAD salvage pathway, glycolysis/gluconeogenesis 657 and TCA cycle during different stages of type 1 diabetes development. The data were 658 downloaded from the Human Pancreas Analysis Program (HPAP) data portal 659 (https://hpap.pmacs.upenn.edu/) and processed ad described in material and methods. 660 Abbreviations: AAB1+ - individuals seropositive for 1 islet autoantibody, AAB2+ - individuals 661 seropositive for multiple islet autoantibodies, beta – β cells, T1D – type 1 diabetes.